aluates Reports

$ 0.0

Automative

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-39O1058

Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market Insights and Forecast to 2028

BUY CHAPTERS

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report 2025

Code: QYRE-Auto-39O1058

Report

September 2025

Pages:90

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Teijin Pharma

Shire Plc

Pfizer Inc

Octapharma AG

Momenta Pharmaceuticals

Mitsubishi Tanabe Pharma Corporation

Kedrion S p A

Baxter

MedDay Pharmaceuticals

GeNeuro Pharmaceuticals

CSL Behring

Grifols

Grifols S A

CSL Behring (CSL Limited)

Bio Products Laboratory

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

The global market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission - recurrence.

North American market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) include Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, CSL Behring (CSL Limited), Bio Products Laboratory, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report

Report Metric	Details
Report Name	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Segment by Type	Corticosteroid Therapy IVIG Treatment Plasma Exchange Therapy Immunosuppressive Drug Therapy Immunomodulator Therapy Other
Segment by Application	Hospital Specialist Neurology Clinic Research and Academic Laboratories
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, CSL Behring (CSL Limited), Bio Products Laboratory, Baxter, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market report?

Ans: The main players in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market are Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, CSL Behring (CSL Limited), Bio Products Laboratory, Baxter, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals

What are the Application segmentation covered in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market report?

Ans: The Applications covered in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market report are Hospital, Specialist Neurology Clinic, Research and Academic Laboratories

What are the Type segmentation covered in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market report?

Ans: The Types covered in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market report are Corticosteroid Therapy, IVIG Treatment, Plasma Exchange Therapy, Immunosuppressive Drug Therapy, Immunomodulator Therapy, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Corticosteroid Therapy

1.2.3 IVIG Treatment

1.2.4 Plasma Exchange Therapy

1.2.5 Immunosuppressive Drug Therapy

1.2.6 Immunomodulator Therapy

1.2.7 Other

1.3 Market by Application

1.3.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Specialist Neurology Clinic

1.3.4 Research and Academic Laboratories

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Perspective (2020-2031)

2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Growth Trends by Region

2.2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Region (2020-2025)

2.2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Region (2026-2031)

2.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics

2.3.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry Trends

2.3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers

2.3.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges

2.3.4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue

3.1.1 Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Revenue (2020-2025)

3.1.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Players (2020-2025)

3.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue

3.4 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio

3.4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2024

3.5 Global Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Head office and Area Served

3.6 Global Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Product and Application

3.7 Global Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Type

4.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Type (2020-2025)

4.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2026-2031)

5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Breakdown Data by Application

5.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Historic Market Size by Application (2020-2025)

5.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2020-2031)

6.2 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025)

6.4 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2020-2031)

7.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025)

7.4 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2020-2031)

8.2 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025)

8.4 Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2020-2031)

9.2 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025)

9.4 Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (2020-2031)

10.2 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025)

10.4 Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Teijin Pharma

11.1.1 Teijin Pharma Company Details

11.1.2 Teijin Pharma Business Overview

11.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.1.4 Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.1.5 Teijin Pharma Recent Development

11.2 Shire

11.2.1 Shire Company Details

11.2.2 Shire Business Overview

11.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.2.4 Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.2.5 Shire Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Details

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.3.4 Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.3.5 Pfizer Recent Development

11.4 Octapharma

11.4.1 Octapharma Company Details

11.4.2 Octapharma Business Overview

11.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.4.4 Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.4.5 Octapharma Recent Development

11.5 Momenta Pharmaceuticals

11.5.1 Momenta Pharmaceuticals Company Details

11.5.2 Momenta Pharmaceuticals Business Overview

11.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.5.4 Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.5.5 Momenta Pharmaceuticals Recent Development

11.6 Mitsubishi Tanabe Pharma Corporation

11.6.1 Mitsubishi Tanabe Pharma Corporation Company Details

11.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview

11.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.6.4 Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.6.5 Mitsubishi Tanabe Pharma Corporation Recent Development

11.7 Kedrion

11.7.1 Kedrion Company Details

11.7.2 Kedrion Business Overview

11.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.7.4 Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.7.5 Kedrion Recent Development

11.8 Grifols

11.8.1 Grifols Company Details

11.8.2 Grifols Business Overview

11.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.8.4 Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.8.5 Grifols Recent Development

11.9 CSL Behring (CSL Limited)

11.9.1 CSL Behring (CSL Limited) Company Details

11.9.2 CSL Behring (CSL Limited) Business Overview

11.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.9.4 CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.9.5 CSL Behring (CSL Limited) Recent Development

11.10 Bio Products Laboratory

11.10.1 Bio Products Laboratory Company Details

11.10.2 Bio Products Laboratory Business Overview

11.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.10.4 Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.10.5 Bio Products Laboratory Recent Development

11.11 Baxter

11.11.1 Baxter Company Details

11.11.2 Baxter Business Overview

11.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.11.4 Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.11.5 Baxter Recent Development

11.12 MedDay Pharmaceuticals

11.12.1 MedDay Pharmaceuticals Company Details

11.12.2 MedDay Pharmaceuticals Business Overview

11.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.12.4 MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.12.5 MedDay Pharmaceuticals Recent Development

11.13 GeNeuro Pharmaceuticals

11.13.1 GeNeuro Pharmaceuticals Company Details

11.13.2 GeNeuro Pharmaceuticals Business Overview

11.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Introduction

11.13.4 GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

11.13.5 GeNeuro Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Teijin Pharma

Shire Plc

Pfizer Inc

Octapharma AG

Momenta Pharmaceuticals

Mitsubishi Tanabe Pharma Corporation

Kedrion S p A

Baxter

MedDay Pharmaceuticals

GeNeuro Pharmaceuticals

CSL Behring

Grifols

Grifols S A

CSL Behring (CSL Limited)

Bio Products Laboratory

List of Tables

Table 1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Corticosteroid Therapy

Table 3. Key Players of IVIG Treatment

Table 4. Key Players of Plasma Exchange Therapy

Table 5. Key Players of Immunosuppressive Drug Therapy

Table 6. Key Players of Immunomodulator Therapy

Table 7. Key Players of Other

Table 8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025) & (US$ Million)

Table 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2020-2025)

Table 12. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 13. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2026-2031)

Table 14. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends

Table 15. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers

Table 16. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Challenges

Table 17. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints

Table 18. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players (2020-2025)

Table 20. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2024)

Table 21. Ranking of Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Headquarters and Area Served

Table 24. Global Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Product and Application

Table 25. Global Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Type (2020-2025) & (US$ Million)

Table 28. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2020-2025)

Table 29. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 30. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Type (2026-2031)

Table 31. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2025) & (US$ Million)

Table 32. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2020-2025)

Table 33. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 34. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share by Application (2026-2031)

Table 35. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025) & (US$ Million)

Table 37. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031) & (US$ Million)

Table 38. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025) & (US$ Million)

Table 40. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031) & (US$ Million)

Table 41. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 42. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2020-2025) & (US$ Million)

Table 43. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Region (2026-2031) & (US$ Million)

Table 44. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025) & (US$ Million)

Table 46. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031) & (US$ Million)

Table 47. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2020-2025) & (US$ Million)

Table 49. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Country (2026-2031) & (US$ Million)

Table 50. Teijin Pharma Company Details

Table 51. Teijin Pharma Business Overview

Table 52. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 53. Teijin Pharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 54. Teijin Pharma Recent Development

Table 55. Shire Company Details

Table 56. Shire Business Overview

Table 57. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 58. Shire Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 59. Shire Recent Development

Table 60. Pfizer Company Details

Table 61. Pfizer Business Overview

Table 62. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 63. Pfizer Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 64. Pfizer Recent Development

Table 65. Octapharma Company Details

Table 66. Octapharma Business Overview

Table 67. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 68. Octapharma Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 69. Octapharma Recent Development

Table 70. Momenta Pharmaceuticals Company Details

Table 71. Momenta Pharmaceuticals Business Overview

Table 72. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 73. Momenta Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 74. Momenta Pharmaceuticals Recent Development

Table 75. Mitsubishi Tanabe Pharma Corporation Company Details

Table 76. Mitsubishi Tanabe Pharma Corporation Business Overview

Table 77. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 78. Mitsubishi Tanabe Pharma Corporation Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 79. Mitsubishi Tanabe Pharma Corporation Recent Development

Table 80. Kedrion Company Details

Table 81. Kedrion Business Overview

Table 82. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 83. Kedrion Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 84. Kedrion Recent Development

Table 85. Grifols Company Details

Table 86. Grifols Business Overview

Table 87. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 88. Grifols Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 89. Grifols Recent Development

Table 90. CSL Behring (CSL Limited) Company Details

Table 91. CSL Behring (CSL Limited) Business Overview

Table 92. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 93. CSL Behring (CSL Limited) Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 94. CSL Behring (CSL Limited) Recent Development

Table 95. Bio Products Laboratory Company Details

Table 96. Bio Products Laboratory Business Overview

Table 97. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 98. Bio Products Laboratory Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 99. Bio Products Laboratory Recent Development

Table 100. Baxter Company Details

Table 101. Baxter Business Overview

Table 102. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 103. Baxter Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 104. Baxter Recent Development

Table 105. MedDay Pharmaceuticals Company Details

Table 106. MedDay Pharmaceuticals Business Overview

Table 107. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 108. MedDay Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 109. MedDay Pharmaceuticals Recent Development

Table 110. GeNeuro Pharmaceuticals Company Details

Table 111. GeNeuro Pharmaceuticals Business Overview

Table 112. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product

Table 113. GeNeuro Pharmaceuticals Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025) & (US$ Million)

Table 114. GeNeuro Pharmaceuticals Recent Development

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

Table 118. Authors List of This Report

List of Figures

Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Picture

Figure 2. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Type: 2024 VS 2031

Figure 4. Corticosteroid Therapy Features

Figure 5. IVIG Treatment Features

Figure 6. Plasma Exchange Therapy Features

Figure 7. Immunosuppressive Drug Therapy Features

Figure 8. Immunomodulator Therapy Features

Figure 9. Other Features

Figure 10. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Application (2020-2031) & (US$ Million)

Figure 11. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Application: 2024 VS 2031

Figure 12. Hospital Case Studies

Figure 13. Specialist Neurology Clinic Case Studies

Figure 14. Research and Academic Laboratories Case Studies

Figure 15. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Years Considered

Figure 16. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region: 2024 VS 2031

Figure 19. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Players in 2024

Figure 20. Global Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2024

Figure 22. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2020-2031)

Figure 24. United States Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2020-2031)

Figure 28. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Region (2020-2031)

Figure 36. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2020-2031)

Figure 44. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Share by Country (2020-2031)

Figure 48. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Teijin Pharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 52. Shire Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 53. Pfizer Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 54. Octapharma Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 55. Momenta Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 56. Mitsubishi Tanabe Pharma Corporation Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 57. Kedrion Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 58. Grifols Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 59. CSL Behring (CSL Limited) Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 60. Bio Products Laboratory Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 61. Baxter Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 62. MedDay Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 63. GeNeuro Pharmaceuticals Revenue Growth Rate in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Business (2020-2025)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Demyelinating Diseases Therapeutics Market Research Report 2024

Global Polymyositis Treatment Market Insights Forecast to 2030

Global Parkinson s Disease Treatment Market Insights Forecast to 2030

Global Diabetic Neuropathy Drugs Market Research Report 2024

Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030

Global Neurodegenerative Disease Market Insights Forecast to 2030

Global Diabetic Peripheral Neuropathy Treatment Market Research Report 2024

Global Parkinson s Disease Therapeutics Market Research Report 2025

Global Familial Amyloid Polyneuropathy Therapeutic Market Research Report 2025

Optic Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Guillain Barre Syndrome Treatment Market Research Report 2025

Peripheral Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peyronie s Disease Treatment Market Insights Forecast to 2030

Global Alzheimers and Parkinsons Diseases Market Insights Forecast to 2030

Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Devic s Syndrome Neuromyelitis Optica Treatment Market Insights Forecast to 2030

Rare Neurodegenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Research Report 2024

Global Peripheral Nerve Repair Devices Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions